Edition:
United Kingdom

Anika Therapeutics Inc (ANIK.OQ)

ANIK.OQ on NASDAQ Stock Exchange Global Select Market

44.80USD
24 Apr 2018
Change (% chg)

$-0.01 (-0.02%)
Prev Close
$44.81
Open
$44.99
Day's High
$45.26
Day's Low
$44.39
Volume
32,022
Avg. Vol
36,326
52-wk High
$68.57
52-wk Low
$42.61

Select another date:

Mon, Mar 5 2018

BRIEF-Joseph Darling Named CEO And Director Of Anika Therapeutics

* JOSEPH DARLING NAMED CEO AND DIRECTOR OF ANIKA THERAPEUTICS

BRIEF-Anika Q4 Earnings Per Share $0.53

* ANIKA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Anika Therapeutics Announces Strategic Collaboration With The Institute Of Integrative Biology

* ANIKA THERAPEUTICS ANNOUNCES STRATEGIC COLLABORATION WITH THE INSTITUTE OF INTEGRATIVE BIOLOGY AT THE UNIVERSITY OF LIVERPOOL TO DEVELOP AN INNOVATIVE THERAPY FOR OSTEOARTHRITIS Source text for Eikon: Further company coverage:

BRIEF-Anika Therapeutics Expands Strategic Collaboration With Institute For Applied Life Sciences

* ANIKA THERAPEUTICS EXPANDS STRATEGIC COLLABORATION WITH THE INSTITUTE FOR APPLIED LIFE SCIENCES (IALS) AT THE UNIVERSITY OF MASSACHUSETTS AMHERST TO DEVELOP INNOVATIVE THERAPY FOR RHEUMATOID ARTHRITIS Source text for Eikon: Further company coverage:

BRIEF-Anika Announces FDA 510(K) Clearance For Its Injectable HA-Based Bone Repair Treatment

* ANIKA ANNOUNCES FDA 510(K) CLEARANCE FOR ITS INJECTABLE HA-BASED BONE REPAIR TREATMENT

BRIEF-Anika reports Q3 earnings per share $0.46

* Q3 revenue rose 5 percent to $27.2 million Source text for Eikon: Further company coverage:

BRIEF-Anika completes enrollment in second pivotal phase III trial of cingal

* Anika completes enrollment in second pivotal phase iii trial of cingal for the treatment of knee pain associated with osteoarthritis

Select another date: